



US010959972B2

(12) **United States Patent**  
**Novas et al.**

(10) **Patent No.: US 10,959,972 B2**  
(45) **Date of Patent: \*Mar. 30, 2021**

(54) **METHODS OF TREATING MULTIPLE SCLEROSIS**

(71) Applicant: **Biogen MA Inc.**, Cambridge, MA (US)  
(72) Inventors: **Mark Novas**, Lexington, MA (US); **Rui (Ray) Zhang**, Sharon, MA (US)

(73) Assignee: **BIOGEN MA INC.**, Cambridge, MA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/173,723**

(22) Filed: **Oct. 29, 2018**

(65) **Prior Publication Data**

US 2019/0125710 A1 May 2, 2019

**Related U.S. Application Data**

(63) Continuation of application No. 15/647,036, filed on Jul. 11, 2017, now abandoned, which is a (Continued)

(51) **Int. Cl.**  
**A61K 31/225** (2006.01)  
**A61K 31/40** (2006.01)  
(Continued)

(52) **U.S. Cl.**  
CPC ..... **A61K 31/225** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/28** (2013.01);  
(Continued)

(58) **Field of Classification Search**  
CPC ..... **A61K 31/225**  
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,959,389 A 9/1990 Speiser et al.  
6,436,992 B1 8/2002 Joshi et al.  
(Continued)

FOREIGN PATENT DOCUMENTS

CN 103732062 A 4/2014  
JP 2009-528359 A 8/2009  
(Continued)

OTHER PUBLICATIONS

Babji et al., 2015, "Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis". *Neuropsychiatric Disease and Treatment*, 11:1221-1229.

(Continued)

*Primary Examiner* — Shengjun Wang

(74) *Attorney, Agent, or Firm* — Choate Hall & Stewart LLP; Brenda Herschbach Jarrell; Tracy L. Vrablik

(57) **ABSTRACT**

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

**19 Claims, 5 Drawing Sheets**

